Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: Raising lazarus from the dead

Clinical Infectious Diseases

Volumn 52, Issue SUPPL. 7, 2011, Pages

  Tsuji, Brian T ^a   Okusanya, Olanrewaju O ^b   Bulitta, Jurgen B ^a,c   Forrest, Alan ^a,b   Bhavnani, Sujata M ^a,b   Fernandez, Prabha B ^d   Ambrose, Paul G ^a,b,e,f  

^a UNIVERSITY AT BUFFALO   (United States)

^b INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^c ORDWAY RESEARCH INSTITUTE   (United States)

^d Cempra Pharmaceuticals   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f ICPD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUSIDIC ACID;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL SKIN DISEASE; CELL DEATH; COLONY FORMING UNIT; DRUG DOSE REGIMEN; HUMAN; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG ADMINISTRATION SCHEDULE; FUSIDIC ACID; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME;

EID: 79955768964     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir166     Document Type: Article

References (17)

1. Whitby M. Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1999; 12(Suppl 2):S67-71. (Pubitemid 29406143)
2. O'Neill AJ, Larsen AR, Skov R, Henriksen AS, Chopra I. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol 2007; 45:1505-10. (Pubitemid 46762405)
3. Farrell DJ, Castanheira M, Chopra I. Characterization of global patterns and the genetics of fusidic acid resistance. Clin Infect Dis 2011; 52(Suppl 7);S487-92.
4. Dineen P. Fusidate sodium in treatment of surgical infections. Arch Surg 1968; 96:219-21.
5. Porter IA, Wilson JS. Staphylococcal infections treated with fusidic acid in nurses. Lancet 1963; 2:658-9.
6. Schumer W, Abtahi H. Sodium fusidate in surgical wound infections. Am J Surg 1968; 115:527-30.
7. Turnidge J. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 1999; 12:S23-34. (Pubitemid 29406139)
8. Bulitta JB, Okusanya OO, Forrest A, et al. Population pharmacoki-netics of CEM-102 in healthy subjects. [abstract A1-1932]. In: Programs and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. 2009.
9. Okusanya OO, Tsuji BT, Bulitta JB, et al. The evaluation of pharma-cokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. Diagn Microbiol Infect Dis 2011; Accepted, In-Press.
10. Bulitta JB, Landersdorfer CB, Kinzig M, Holzgrabe U, Sorgel F. New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics. Antimicrob Agents Chemother 2011; 53:3462-71.
11. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition. CLSI document M07-A8 (ISBN 1-56238-689-1).
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19 (ISBN 1-56238-690-5).
13. Bulitta JB, Ly NS, Yang JC, Forrest A, Jusko WJ, Tsuji BT. Development and qualification of a pharmacodynamic model for the pronounced inoculums effect of ceftazidime against Pseudomonas aeruginosa. An-timicrob Agents Chemother 2009; 53:46-56.
14. Harigaya Y, Bulitta JB, Forrest A, et al. Pharmacodynamics of vanco-mycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Anti-microb Agents Chemother 2009; 53:3494-901.
15. Moriarty SR, Clark K, Scott D, et al. Efficacy and safety of CEM-102 in a Phase 2, randomized, double-blind study in patients with acute bacterial skin and skin structure infections [abstract L1-1762]. In: Program and abstracts of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (Boston, MA). Washington, DC: American Society of Microbiology, 2010.
16. Gordi T, Xie R, Huong NV, Huong DX, Karlsson MO, Ashton M. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol 2005; 59:189-98. (Pubitemid 40208855)
17. Gordi T, Xie R, Jusko WJ. Semi-mechanistic pharmacokinetic/ pharmacodynamic modeling of the antimalarial effect of artemisinin. Br J Clin Pharmacol 2005; 60:594-604. (Pubitemid 41705378)